Stereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19
- 11 November 2003
- Vol. 16 (1) , 36-44
- https://doi.org/10.1002/chir.10303
Abstract
Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP. Methadone is a chiral drug administered as the racemic mixture of (R)-(–)- and (S)-(+)-methadone, but (R)-methadone is the active isomer. The cytochrome P450 (CYP) isoform involved in methadone's metabolism is thought to be CYP3A4, but human drug–drug interaction studies are not consistent with this. The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively. Only CYP2B6, 2C19, and 3A4 generated measurable EDDP from 1 μg/ml of racemic methadone. The hierarchy of EDDP generation was CYP2B6 > CYP2C19 ≥ CYP3A4. At 10 μg/ml of methadone, CYP2C9 and CYP2D6 also generated EDDP, but in at least 10-fold lower quantities than CYP2B6. Michaelis-Menten kinetic data demonstrated that CYP2B6 had the highest Vmax (44 ng/min/10pmol) and the lowest Km (12.6 μg/ml) for EDDP formation of all the CYP isoforms. In human liver microsomes with high and low CYP2B6 expression but equivalent CYP3A4 expression, high CYP2B6 expression microsomes generated twice the amount of EDDP from 10 μg/ml of methadone than low CYP2B6 expression microsomes. When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. These data suggest that multiple CYPs metabolized methadone but CYP2B6 had the highest Vmax/Km. In addition, only CYP2B6 and 2C19 showed stereoselective metabolism. Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Chirality 16:36–44, 2004.Keywords
This publication has 24 references indexed in Scilit:
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenzBritish Journal of Clinical Pharmacology, 2001
- Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy MalesAntimicrobial Agents and Chemotherapy, 2001
- Methadone N‐demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4British Journal of Clinical Pharmacology, 1999
- THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*Drug Metabolism Reviews, 1999
- Effective Medical Treatment of Opiate AddictionJAMA, 1998
- Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug usersDrug and Alcohol Dependence, 1996
- Involvement of Cytochrome P450 3A4 Enzyme in the N-Demethylation of Methadone in Human Liver MicrosomesChemical Research in Toxicology, 1996
- The biotransformation of methadone in man: Synthesis and identification of a major metaboliteJournal of Pharmacy and Pharmacology, 1968